Director at Humacyte (NASDAQ: HUMA) granted 80,000 stock options

Rhea-AI Filing Summary

Humacyte director Diane Seimetz received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. This is a compensation-related award, not an open-market purchase. Following the grant, she holds options on 80,000 shares directly. The footnote states that 25% of the options vest on June 11, 2027, with the remainder vesting in equal monthly installments through June 11, 2030.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Seimetz Diane

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	80,000	$0.00	--

Holdings After Transaction: Stock Options (right to buy) — 80,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 80,000 options Exercise price: $1.08 per share Expiration date: June 11, 2036 +4 more

7 metrics

Options granted 80,000 options Grant of stock options to director Diane Seimetz

Exercise price $1.08 per share Strike price for Humacyte common stock under the option

Expiration date June 11, 2036 Option term end date

Underlying shares 80,000 shares Humacyte common stock subject to options

Post-transaction derivative holdings 80,000 options Total derivative securities held after grant

Initial vesting date June 11, 2027 First 25% of option becomes exercisable

Monthly vesting pattern 1/48 per month Remaining options vest monthly through June 11, 2030

Key Terms

Stock Options (right to buy), Common Stock, exercise price, vesting

4 terms

Stock Options (right to buy) financial

"security_title: Stock Options (right to buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: 1.0800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"1/48 of the option will become exercisable on the 11th of each month"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seimetz Diane

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.08	06/11/2026		A		80,000		(1)	06/11/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

	/s/ Diane Seimetz by Dale A. Sander as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Humacyte (HUMA) director Diane Seimetz report in this Form 4 filing?

Humacyte director Diane Seimetz reported receiving a grant of stock options for 80,000 shares of common stock. These options are a compensation-related award, not a market purchase, and give her the right to buy Humacyte shares at a fixed exercise price.

How many Humacyte (HUMA) stock options were granted to Diane Seimetz and at what price?

Diane Seimetz was granted options to buy 80,000 shares of Humacyte common stock at an exercise price of $1.08 per share. This grant represents a right to purchase shares in the future rather than an immediate stock acquisition.

What is the vesting schedule for Diane Seimetz’s Humacyte (HUMA) stock options?

The options vest 25% on June 11, 2027, then 1/48 of the grant vests monthly on the 11th through June 11, 2030. This creates a multi-year vesting schedule that ties the award to ongoing service with Humacyte.

When do Diane Seimetz’s Humacyte (HUMA) stock options expire?

The stock options granted to Diane Seimetz expire on June 11, 2036. She may exercise vested portions any time before that date, subject to plan terms, by paying the $1.08 per share exercise price to acquire Humacyte common stock.

How many Humacyte (HUMA) derivative securities does Diane Seimetz hold after this transaction?

After this grant, Diane Seimetz holds derivative securities representing 80,000 underlying shares of Humacyte common stock. All of these are from this single stock option award, held directly, with vesting spread between 2027 and 2030 under the disclosed schedule.